Clinical trials: Breath Shortness
Dyspnea
Evaluation of Transient Dyspnea During Gadoxetic Acid Enhanced Multiphasic Liver MRI
The purpose of this study is to observe transient dyspnea pattern after Gd-EOB-DTPA administration by obtaining continuous dynamic T1 weighted image data.
- Trial name
- NCT02395991
- Testing
- gadoxetic acid, Magnetic resonance imaging (MRI)
- Where
- South Korea
- Volunteers
- 60 people
- Sponsor
- Seoul National University Hospital
Dyspnea, Hypercapnia
Clinical Efficacy in Relief of Dyspnea by HVNI: Evaluation of New Cannulae Designs
This study will evaluate the ability of High Velocity Nasal Insufflation [HVNI] next generation nasal cannula designs to effect ventilation and related physiological responses relative to the conventional legacy cannula design.
- Conditions
- Dyspnea, Hypercapnia, Respiratory Insufficiency
- Trial name
- NCT04512781
- Testing
- Control Cannula - Prosoft Cannula - Unicorn Cannula, Control Cannula - Unicorn Cannula - Prosoft Cannula
- Where
- 2 sites in United States
- Volunteers
- 26 people
- Sponsor
- Vapotherm, Inc.
Chronic Obstructive Pulmonary Disease
The Effect of QVA149 on Patient Reported Dyspnea in Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)
This study assessed the effect of QVA149 on patient-reported dyspnea in moderate to severe Chronic Obstructive Pulmonary Disease (COPD) patients.
- Trial name
- BLAZE (NCT01490125)
- Testing
- QVA149, Tiotropium, Salbutamol/albuterol
- Where
- 43 sites in Belgium, Canada and 3 more
- Volunteers
- 247 people
- Sponsor
- Novartis Pharmaceuticals
Asthma
Efficacy and Safety Study of QAW039 in Patients With Severe Asthma Inadequately Controlled With Standard of Care Asthma Treatment.
This study aimed to determine the efficacy and safety of QAW039 150 mg and QAW039 450 mg, compared with placebo, when added to GINA (Global Initiative for Asthma) steps 4 and 5 standard-of- care (SoC) asthma therapy (GINA 2016)…
- Trial name
- NCT02555683
- Testing
- QAW039
- Where
- 234 sites in United States, Argentina and 25 more
- Volunteers
- 894 people
- Sponsor
- Novartis Pharmaceuticals
Asthma
A Study of Omalizumab (Xolair) in Subjects With Moderate to Severe Persistent Asthma (EXTRA)
This is a multicenter, randomized, double-blind, placebo-controlled study of the efficacy, safety, and tolerability of subcutaneously administered Xolair as add-on therapy for the treatment of subjects aged 12-75 years old…
- Trial name
- NCT00314574
- Testing
- omalizumab (Xolair), corticosteroids, long-acting beta-agonists
- Volunteers
- 850 people
- Sponsor
- Genentech, Inc.
COPD, Chronic Bronchitis
The Effectiveness of Roflumilast in Improving Mucociliary Clearance in Patients With COPD and Chronic Bronchitis
Specific Aim: To determine the effectiveness of Roflumilast in improving i) whole right lung and ii) peripheral right lung mucociliary clearance (MCC) in patients with COPD and chronic bronchitis.
- Conditions
- COPD, Chronic Bronchitis, Emphysema
- Trial name
- NCT03073798
- Testing
- Roflumilast
- Volunteers
- 12 people
- Sponsor
- Johns Hopkins University
Acute Heart Failure
Renal Optimization Strategies Evaluation in Acute Heart Failure and Reliable Evaluation of Dyspnea in the Heart Failure Network (ROSE) Study
The purpose of this study is to determine the benefits and safety of intravenous administration of low dose nesiritide or low dose dopamine in patients with congestive heart failure and kidney dysfunction.
- Trial name
- ROSE/RED ROSE (NCT01132846)
- Testing
- Nesiritide, Dopamine
- Where
- 8 sites in United States, Canada
- Volunteers
- 360 people
- Sponsor
- Duke University
Chronic Obstructive Pulmonary Disease
An Exploratory Study, to Assess the Effect of Repeat-dose Inhaled Indacaterol Maleate (300 μg) on Dynamic and Static Lung Hyperinflation, Subjective Breathlessness and Health Status in Patients With Chronic Obstructive Pulmonary Disease(COPD)
This study evaluated the effect of QAB149 on dynamic and static hyperinflation, breathlessness, and health status in COPD patients
- Trial name
- NCT00636961
- Testing
- Indacaterol 300μg
- Where
- 3 sites in Germany
- Volunteers
- 27 people
- Sponsor
- Novartis
Hypertrophic Cardiomyopathy
Effect of Eleclazine (GS-6615) on Exercise Capacity in Subjects With Symptomatic Hypertrophic Cardiomyopathy
The primary objective of this study was to evaluate the effect of eleclazine (GS-6615) on exercise capacity as measured by Peak oxygen uptake (VO2) achieved during cardiopulmonary exercise testing (CPET), in participants with…
- Trial name
- LIBERTY-HCM (NCT02291237)
- Testing
- Eleclazine
- Where
- 46 sites in United States, Australia and 6 more
- Volunteers
- 172 people
- Sponsor
- Gilead Sciences
Pulmonary Arterial Hypertension
Safety, Pharmacokinetics and Efficacy Study of QCC374 in PAH Patients
This was a non-confirmatory, randomized, placebo controlled, subject and investigator blinded study of QCC374 in PAH subjects. The study was planned to have 2 Parts: Part 1, an initial safety cohort with a 0.03 mg bid starting…
- Trial name
- NCT02927366
- Testing
- QCC374
- Where
- 5 sites in United States, Germany and 2 more
- Volunteers
- 8 people
- Sponsor
- Novartis Pharmaceuticals
Asthma
Bronchodilator Effects and Safety of Glycopyrronium Bromide (25 ug and 50 ug o.d.) in Asthma
The purpose of this trial is to characterize the bronchodilator effects and safety of 25 ug and 50 ug o.d. NVA237 (glycopyrronium bromide) doses compared to placebo in asthma patients
- Trial name
- NCT03137784
- Testing
- NVA237 (glycopyrronium bromide)
- Where
- 21 sites in United States, Belgium and 4 more
- Volunteers
- 148 people
- Sponsor
- Novartis Pharmaceuticals
Death, Pain
Intervention to Improve Care at Life's End
The BEACON trial (Best Practices for End-of-Life Care for Our Nations' Veterans) was a six-site implementation study to evaluate a multi-component, education-based intervention to improve the quality of end-of-life care provided…
- Conditions
- Death, Pain, Dyspnea
- Trial name
- BEACON (NCT00234286)
- Testing
- Comfort care education intervention
- Where
- United States
- Volunteers
- 78 people
- Sponsor
- US Department of Veterans Affairs
Dyspnea, Lactic Acidosis
Effect of High Velocity/Hyperoxic Breathing Therapy on Blood Lactate Decline
The study will evaluate the impact of high velocity therapy (HVT) on reduction of work of breathing (as implied by breath frequency) and enhanced blood lactate decline during recovery from a Wingate-type Exercise test.
- Conditions
- Dyspnea, Lactic Acidosis, Muscle, Breathlessness
- Trial name
- NCT05984186
- Testing
- High Velocity Therapy
- Where
- United States
- Volunteers
- 15 people, healthy volunteers welcome
- Sponsor
- Vapotherm, Inc.
Lung Cancer
Reducing Lung Cancer-Related Anxiety (RELAX)
The purpose of this research study is to compare the effects of music and different levels of device-guided breathing on anxiety and shortness of breath in lung cancer survivors.
- Trial name
- RELAX (NCT02063828)
- Testing
- Group A - Device guided breathing low dose, Group B - Device guided breathing high dose, Group C - Usual Breathing Control Group
- Where
- 11 sites in United States
- Volunteers
- 46 people
- Sponsor
- Wake Forest University Health Sciences
Dyspnea, Malignant Neoplasm
Dexamethasone in Controlling Dyspnea in Patients With Cancer
This phase II trial studies how well dexamethasone works in controlling dyspnea in patients with cancer. Dexamethasone may help control dyspnea (shortness of breath) and improve lung function and quality of life in cancer…
- Trial name
- NCT03367156
- Testing
- Dexamethasone, Questionnaire Administration
- Where
- 3 sites in United States
- Volunteers
- 135 people
- Sponsor
- M.D. Anderson Cancer Center
COPD, Interstitial Lung Disease
An Observational Outcomes Study for Autologous Cell Therapy Among Patients With COPD and Interstitial Lung Disease
The purpose of the Lung Institute is to collect and isolate a patient's own cells and platelet rich plasma (PRP) and deliver the product back to the patient same-day.
- Trial name
- NCT03040674
- Testing
- Cell therapy
- Where
- United States
- Volunteers
- 489 people
- Sponsor
- Lung Institute
Asthma, Bronchospasm
Epinephrine Inhalation Aerosol USP, a HFA-MDI Study for Assessment of Pharmacokinetics
This study examines the pharmacokinetic profile of Armstrong's proposed Epinephrine Inhalation Aerosol USP, an HFA-MDI (E004), using a stable isotope deuterium-labeled epinephrine (epinephrine-d3) to differentiate the…
- Conditions
- Asthma, Bronchospasm, Wheezing, Shortness of Breath
- Trial name
- NCT01188577
- Testing
- Epinephrine Inhalation Aerosol, HFA, Epinephrine Inhalation Aerosol
- Where
- United States
- Volunteers
- 23 people, healthy volunteers welcome
- Sponsor
- Amphastar Pharmaceuticals, Inc.
Sepsis
Project 4A: Inspiratory Muscle Training and Diaphragm Strength
Investigators will assess the effect of exercise on markers of inflammation and protein catabolism. This research study will further our understanding of how treating Chronic Critical illness (CCI) - related respiratory muscle…
- Trial name
- NCT02367170
- Testing
- Bilateral phrenic nerve stimulation and measurement of transdiaphragmatic pressure, Midazolam, Volitional Measurement of Maximal Inspiratory Pressure (MIP)
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- University of Florida
Lung Cancer
Brief Behavioral Intervention for Dyspnea in Patients With Advanced Lung Cancer
This research study is evaluating a behavioral intervention designed to help people with advanced lung cancer manage dyspnea (i.e., breathlessness or shortness-of-breath).
- Trial name
- NCT03089125
- Testing
- Dyspnea Intervention, Usual Care
- Where
- 2 sites in United States
- Volunteers
- 247 people
- Sponsor
- Massachusetts General Hospital
Chronic Obstructive Pulmonary Disease (COPD)
Safety and Efficacy of Indacaterol Once Daily Versus Salmeterol Twice Daily in Chronic Obstructive Pulmonary Disease (COPD)
This study compared the safety and efficacy of indacaterol 150 µg taken once daily (o.d.) versus salmeterol 50 µg taken twice daily (b.i.d) in patients 40 years old or older with chronic obstructive pulmonary disease.
- Trial name
- INSIST (NCT00821093)
- Testing
- Indacaterol 150 µg, Salmeterol 50 µg
- Where
- 144 sites in United States, Czechia and 6 more
- Volunteers
- 1,123 people
- Sponsor
- Novartis Pharmaceuticals